| Literature DB >> 30688681 |
Alexander M Girgis1, Eugene Golts2, Doug Humber3, Dalia A Banks1.
Abstract
Heparin is the only well-established anticoagulant medication for cardiopulmonary bypass making selecting an alternative anticoagulant challenging in patients with heparin-induced thrombocytopenia. Other anticoagulant medications can cause significant postoperative bleeding, especially in patients with end-stage renal disease. We present a case of a 63-year-old woman requiring aortic valve replacement with a history of heparin-induced thrombocytopenia and end-stage renal disease. Cangrelor and heparin were successfully used during cardiopulmonary bypass, offering an option for anticoagulation management for a uniquely challenging patient population.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30688681 DOI: 10.1213/XAA.0000000000000969
Source DB: PubMed Journal: A A Pract ISSN: 2575-3126